FOXP3 inhibits NF-κB activity and hence COX2 expression in gastric cancer cells

Qiang Hao1, Cun Zhang1, Yuan Gao1

  • 1The State Key Laboratory of Cancer Biology, School of Pharmacy, Department of Biopharmaceutics, The Fourth Military Medical University, Xi'an 710032, China.

Cellular Signalling
|December 7, 2013
PubMed

Insights

Forkhead box protein 3 (FOXP3) acts as a tumor suppressor in gastric cancer by inhibiting nuclear factor kappa B (NF-κB) activity. This regulation reduces the expression of COX2, thereby decreasing cancer cell migration and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gastric cancer is a leading cause of cancer mortality worldwide.
  • Upregulated cyclooxygenase-2 (COX2) is implicated in gastric cancer development.
  • The precise regulatory mechanisms of COX2 in gastric cancer remain largely unknown.

Purpose of the Study:

  • To elucidate the regulatory mechanisms of COX2 during gastric cancer progression.
  • To investigate the role of nuclear factor kappa B (NF-κB) and its relationship with COX2.
  • To identify novel regulators of NF-κB activity in gastric cancer.

Main Methods:

  • Correlation analysis between COX2 expression and NF-κB activity.
  • Assessment of NF-κB nuclear localization versus transcriptional activity.
  • Investigation of Forkhead box protein 3 (FOXP3) expression and its interaction with NF-κB.
  • FOXP3 knockdown experiments to evaluate effects on NF-κB, COX2, and cell migration.

Main Results:

  • COX2 expression positively correlated with NF-κB activity.
  • NF-κB nuclear localization did not always align with its transcriptional activity.
  • FOXP3 expression inversely correlated with NF-κB activity, interacting with NF-κB to repress its function.
  • FOXP3 knockdown led to increased NF-κB activity, elevated COX2 expression, and enhanced cell migration.

Conclusions:

  • FOXP3 functions as a negative regulator of NF-κB activity in gastric cancer.
  • FOXP3 exerts a tumor suppressor role by inhibiting NF-κB-mediated COX2 expression.
  • Targeting FOXP3-NF-κB pathway may offer therapeutic strategies for reducing gastric cancer metastasis.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.6K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
44
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
52